Extended Data Fig. 6: Increased efficacy of CAR T cells engineered to inactivate PARP11.
From: Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors
a qPCR analysis of PARP11 mRNA in shCON-CD19-BBz or shPARP11-CD19-BBz CAR T cells. Data are shown as mean ± SEM (n = 5 independently treated cell cultures.). Two-tailed unpaired t-test was performed for the comparisons between groups. ****P < 0.0001. b Flow cytometry analysis of CAR expression in human T cells 3 days after shCON-CD19-BBz or shPARP11-CD19-BBz transduction. c In vitro proliferation of shCON-CD19-BBz and shPARP11-CD19-BBz CAR T cells following stimulation with anti-CD3/CD28 microbeads. Data are shown as mean ± SEM (n = 3 independently treated cell cultures). Statistical analysis was performed using two-way ANOVA with Tukey’s multiple comparisons test. d qPCR analysis of PARP11 mRNA in human WT or PARP11 knockout (PARP11 sgRNA) Meso–BBz CAR T cells. Data are shown as mean ± SEM (n = 5 independently treated cell cultures). Two-tailed unpaired t-test was performed for the comparisons between groups. ****P < 0.0001. e Flow cytometry analysis of IFNAR1 cell surface levels on human WT or PARP11 knockout (PARP11 sgRNA) Meso–BBz CAR T cells. Data are shown as mean ± SEM (n = 5 independently treated cell cultures). Two-tailed unpaired t-test was performed for the comparisons between groups. *P = 0.0128. f Analysis of killing of EM-Meso-GFP-Luc cells cocultured with human WT or PARP11 knockout (PARP11 sgRNA) Meso–BBz CAR T cells. Data are shown as mean ± SEM (n = 5 independently treated cell cultures). Two-tailed unpaired t-test was performed for the comparisons between groups. ***P = 0.0006.
